Table 2.
Participant’s baseline characteristics by neurocognitive status among HIV-infected participants of National NeuroAIDS Tissue Consortium (NNTC).
| Variables | Global T scoresa | p value | |
|---|---|---|---|
| Unimpaired > 40 | Impaired ≤ 40 | ||
| n (%)b | n (%)b | ||
| Total | 527c (60.1) | 350c (39.1) | |
| Gender | |||
| Male | 424 (80.5) | 271 (77.4) | 0.2791* |
| ARV medication use | 0.0157* | ||
| No current ARV | 45 (9.1) | 29 (8.9) | |
| Current non-cART | 49 (9.8) | 59 (18.0) | |
| Current cART | 402 (81.1) | 239 (73.1) | |
| Race | 0.003* | ||
| White | 266 (51.9) | 211 (61.7) | |
| Black | 215 (42.0) | 98 (28.6) | |
| Other | 33 (9.6) | 33 (9.6) | |
| Ethnicity | < 0.0001* | ||
| Hispanic or Latino | 119 (22.6) | 126 (36.0) | |
| Not Hispanic or Latino | 408 (77.4) | 224 (64.0) | |
| Hypertension history | 121 (29.9) | 62 (25.4) | 0.2138* |
| Diabetes history | 46 (11.39) | 43 (17.7) | 0.0242* |
| Hyperlipidemia history | 100 (24.7) | 48 (19.6) | 0.1291* |
| Viral hepatitis history | 139 (34.5) | 104 (42.8) | 0.0340* |
| End stage liver disease history | 9 (2.2) | 8 (3.3) | 0.4157* |
| Chronic renal disease history | 30 (7.5) | 17 (7.0) | 0.8252* |
| Cardiac disease history | 40 (9.9) | 26 (10.7) | 0.7611* |
| Chronic obstructive pulmonary disease | 44 (10.9) | 24 (9.8) | 0.6563* |
| Cerebrovascular disease history | 33 (8.2) | 43 (17.7) | 0.0005* |
| Non-AIDS defining cancers | 31 (7.7) | 15 (6.2) | 0.4622* |
| Any non-AIDS defining comorbidityd | 287 (70.7) | 181 (73.9) | 0.3811* |
| Any CNS comorbiditye | 29 (5.9) | 44 (13.4) | 0.0002* |
| Alcohol use history | 224 (61.5) | 98 (45.5) | 0.0030* |
| Cannabis use history | 151 (41.5) | 62 (28.6) | 0.0379* |
| Cocaine use history | 198 (54.4) | 87 (40.1) | 0.0008* |
| Hallucinogen use history | 28 (7.7) | 16 (7.4) | 0.8883* |
| Opiate use history | 63 (17.3) | 42 (19.3) | 0.5345* |
| Sedative use history | 38 (10.4) | 24 (11.1) | 0.8149* |
| Stimulant use historye | 86 (23.6) | 39 (17.9) | 0.1089* |
| Mean (SD) | Mean (SD) | ||
|---|---|---|---|
| Age (years) | 47.1 (10.7) | 46.5 (10.6) | 0.5779** |
| Years of education (years) | 12.3 (3.6) | 12.2 (3.2) | 0.5779** |
| Beck's Depression Inventory (BDI) total score | 13.1 (10.1) | 15.4 (10.4) | 0.0001** |
| Hemoglobin (g/dl) | 13.4 (1.8) | 13.2 (1.9) | 0.0395** |
| CD4 Nadir (cells/µl) | 138.7 (213.6) | 138.1 (210.0) | 0.9744** |
| CD4 cell count (cells/µl) | 301.9 (298.8) | 273.1 (273.5) | 0.1565** |
| Plasma viral load (log10 copies/ml) | 2.9 (1.3) | 3.1 (1.4) | 0.0561** |
| Number of non-AIDS defining comorbiditiesd | 1.4 (1.3) | 1.6 (1.5) | 0.2521** |
| Number of CNS comorbiditiesf | 0.05 (0.2) | 0.1 (0.4) | < .0001** |
| Duration of HIV (years) | 13.3 (7.4) | 12.7 (7.6) | 0.1615** |
| Number of substances usedg | 2.1 (1.7) | 1.6 (1.7) | 0.0323** |
*Cochran Mantel–Haenszel statistics (score = modified ridit). **Analysis of variance.
aScores range between 0 and 100 and higher T scores imply better neurocognitive status.
bColumn percentages.
cSample size may be lower for variables due to missing data.
dIncludes history of hypertension, diabetes, viral hepatitis, end-stage liver disease, hyperlipidemia, chronic renal disease, cardiac disease, chronic obstructive pulmonary disease, and cerebrovascular disease.
eDefined as use of amphetamines, diet pills, ice, khat, methamphetamine, Ritalin, speed and uppers.
fPrimary CNS lymphoma, toxoplasma encephalitis, progressive multifocal leukoencephalopathy, CMV ventriculo-encephalitis, cryptococcal meningitis, histoplasma meningitis, coccidiodes meningitis, tuberculous meningitis, syphilitic meningitis, lymphomatous meningitis, and other specific meningitis.
gIncludes history of alcohol, cannabis, cocaine, hallucinogen, opiate, sedative and stimulant use.